1. Home
  2. EDAP vs ALXO Comparison

EDAP vs ALXO Comparison

Compare EDAP & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$3.73

Market Cap

75.5M

Sector

Health Care

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.38

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDAP
ALXO
Founded
1979
2015
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.5M
68.3M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
EDAP
ALXO
Price
$3.73
$1.38
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$8.50
$3.30
AVG Volume (30 Days)
80.7K
186.5K
Earning Date
11-06-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$74,853,925.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.61
N/A
52 Week Low
$1.21
$0.40
52 Week High
$4.00
$2.27

Technical Indicators

Market Signals
Indicator
EDAP
ALXO
Relative Strength Index (RSI) 68.40 52.43
Support Level $3.53 $1.07
Resistance Level $3.45 $1.18
Average True Range (ATR) 0.29 0.10
MACD 0.05 -0.00
Stochastic Oscillator 76.92 60.87

Price Performance

Historical Comparison
EDAP
ALXO

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: